Kiniksa Pharmaceuticals International, plc
KNSA
Rankning i aktier
#2958
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aktiekurs
$79.61
Senast synkroniserad: 2026-10-19
Marknadsvärde
$6.21B
Förändring (1 dag)
1.30%
Förändring (1 år)
104.18%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
EPS för Kiniksa Pharmaceuticals International, plc (KNSA)
EPS per June 2026 TTM: $1.07
Enligt Kiniksa Pharmaceuticals International, plcs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $1.07. Vid slutet av 2023 hade bolaget ett EPS på $0.20, en minskning jämfört med EPS från 2022 som var $2.64.
EPS-historik för Kiniksa Pharmaceuticals International, plc från 2016 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $1.07 | -278.33% |
| 2024 | $-0.60 | -400.00% |
| 2023 | $0.20 | -92.42% |
| 2022 | $2.64 | -214.78% |
| 2021 | $-2.30 | -11.88% |
| 2020 | $-2.61 | -12.71% |
| 2019 | $-2.99 | -14.33% |
| 2018 | $-3.49 | 74.50% |
| 2017 | $-2.00 | 170.27% |
| 2016 | $-0.74 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $2.41 | 125.23% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -51.40% |
US
|
